LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Lista de Ações・Kura Oncology Inc
Search

Kura Oncology Inc

Fechado

SetorSaúde

8.74 -0.91

Compra Forte

Atualização de preço 10 de jun. de 2026, 19:59 UTC

ComprarVender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

8.69

Máximo

9.1

Indicadores-chave

By Trading Economics

Rendimento

7.7M

-73M

Vendas

929K

18M

EPS

-0.828

Margem de lucro

-401.495

Funcionários

260

EBITDA

7.4M

-78M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+219.07% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de ago. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-84M

760M

Abertura anterior

9.65

Fecho anterior

8.74

Sentimento de Notícias

By Acuity

100%

0%

320 / 344 Ranking em Healthcare

Kura Oncology Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de jun. de 2026, 23:36 UTC

Ganhos

Correction to Oracle Reports Higher 4Q Profit Article

DJ

Ler

10 de jun. de 2026, 23:19 UTC

Ações em Alta

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

DJ

Ler

10 de jun. de 2026, 23:09 UTC

Grandes Movimentos do Mercado

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

DJ

Ler

10 de jun. de 2026, 23:04 UTC

Ganhos

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

DJ

Ler

10 de jun. de 2026, 20:44 UTC

Grandes Movimentos do Mercado

Caterpillar Raises Quarterly Dividend 8%

DJ

Ler

10 de jun. de 2026, 23:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott: Northern Star Should Take No Options Off The Table

DJ

Ler

10 de jun. de 2026, 23:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

DJ

Ler

10 de jun. de 2026, 23:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

DJ

Ler

10 de jun. de 2026, 23:47 UTC

Conversa de Mercado

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

DJ

Ler

10 de jun. de 2026, 23:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

DJ

Ler

10 de jun. de 2026, 23:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

DJ

Ler

10 de jun. de 2026, 23:38 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

DJ

Ler

10 de jun. de 2026, 23:38 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

DJ

Ler

10 de jun. de 2026, 23:38 UTC

Conversa de Mercado

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

DJ

Ler

10 de jun. de 2026, 23:32 UTC

Conversa de Mercado

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

DJ

Ler

10 de jun. de 2026, 23:20 UTC

Conversa de Mercado

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

DJ

Ler

10 de jun. de 2026, 22:05 UTC

Conversa de Mercado

Correction to Bank of Canada Stays on Hold Market Talk

DJ

Ler

10 de jun. de 2026, 21:57 UTC

Ganhos

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Ler

10 de jun. de 2026, 21:52 UTC

Ganhos

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Ler

10 de jun. de 2026, 21:35 UTC

Ganhos

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Ler

10 de jun. de 2026, 21:22 UTC

Ganhos

Oracle Stock Slides on Increased Capital Spending -- WSJ

DJ

Ler

10 de jun. de 2026, 20:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

DJ

Ler

10 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

DJ

Ler

10 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

DJ

Ler

10 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

DJ

Ler

10 de jun. de 2026, 20:39 UTC

Conversa de Mercado
Ganhos

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

DJ

Ler

10 de jun. de 2026, 20:34 UTC

Ganhos

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Ler

10 de jun. de 2026, 20:33 UTC

Ganhos

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

DJ

Ler

10 de jun. de 2026, 20:33 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

DJ

Ler

10 de jun. de 2026, 20:33 UTC

Conversa de Mercado
Ganhos

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

DJ

Ler

Comparação entre Pares

Variação de preço

Kura Oncology Inc Previsão

Preço-alvo

By TipRanks

219.07% parte superior

Previsão para 12 meses

Média 28.11 USD  219.07%

Máximo 40 USD

Mínimo 15 USD

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para Kura Oncology Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

10 ratings

10

Comprar

0

Manter

0

Vender

Com base em 10 analistas que deram avaliações de ações para Kura Oncology Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

320 / 344 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.

Outras ações do setor

LLY

Eli Lilly and Co.

1,136.41

↓-0.5%

JNJ

Johnson and Johnson

238.85

↑ +0.91%

ABBV

AbbVie Inc

225.29

↑ +0.05%

UNH

UnitedHealth Group Inc

407.06

↓-1.28%

MRK

Merck & Co Inc.

119

↓-0.38%
help-icon Live chat